Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 42Recruiting 16Terminated 10Active not recruiting 10Unknown 9Not yet recruiting 4Withdrawn 3Enrolling by invitation 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 73Breast Neoplasms 73Colorectal Neoplasms 39Prostatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 26Uterine Cervical Neoplasms 20Stomach Neoplasms 20Carcinoma, Hepatocellular 20Pancreatic Neoplasms 15Anxiety Disorders 15Leukemia, Myeloid, Acute 14Hematologic Neoplasms 13Colonic Neoplasms 13Urinary Bladder Neoplasms 12Lymphoma, Follicular 12Brain Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Head and Neck Neoplasms 10Esophageal Neoplasms 10Diabetes Mellitus 10Sarcoma 9Ovarian Neoplasms 9Melanoma 9Liver Neoplasms 9Esophageal Squamous Cell Carcinoma 9Rectal Neoplasms 8Pulmonary Disease, Chronic Obstructive 8Epilepsy 8Disease 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Neurofibrosarcoma × Clear all
NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Stella Pharma Corporation

Phase 1/2 Enrolling by invitation
30 enrolled
BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡